Table 1.
Serious toxicities after re-irradiation with stereotactic body radiotherapy for lung tumors in patients previously treated with thoracic radiotherapy
| Authors and Reference number | Number of patients | Tumor location (central/peripheral) | Initial irradiation dosea | Re-SBRT dosea | Non-lung toxicities of grade 4–5 (tumor location) | Lung toxicities of grade 4–5 |
|---|---|---|---|---|---|---|
| Peulen et al. [4] | 29 | 11/21 | 30 Gy/2 Fr 40 Gy/4 Fr |
30 Gy/2 Fr 40 Gy/5 Fr |
G5 hemoptysis: 3 pts (central) G4 othersb: 2 pts (central) |
None |
| Liu et al. [6] | 72 | 4/68 | 63 Gy/Conv | 50 Gy/4 Fr | NA | G5 pneumonitis: 1 pt |
| Reyngold et al. [7] | 39 | NA | 61 Gy/Conv | 70.4 Gy (BED10) | G4 skin: 1 ptc (peripheral) | None |
| Kilburn et al. [10] | 33 | 17/16 | 66 Gy/33 Fr 50 Gy/5 Fr |
50 Gy/10 Fr | G5 aorta-esophageal fistula: 1 pt (central) |
None |
| Trovo et al. [11] | 17 | 17/0 | 50–60 Gy/20–30 Fr | 30 Gy/5–6 Fr | G5 hemoptysis: 1 pt (central) | G5 pneumonitis: 1 pt |
| Parks et al. [17] | 27 | 18/11 | 64.8 Gy/Conv | 50 Gy/5 Fr | G4 chest wall pain: 1 pt | None |
Abbreviations: BED 10 biologically effective dose (α/β = 10), Conv conventional fractionation, Fr fractions, G grade, NA not available, pt patient, Re-SBRT re-irradiation with stereotactic body radiotherapy
aMedian dose or frequently used dose
bVena cava superior stenosis and fistula between the trachea and gastric tube developed in a case with a recurrent tumor at the carina
cSBRT was performed for a right lung tumor in a patient who had received contralateral lung irradiation [19]